Prednisone
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
Explore 31 assets in B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2) →Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
University of Washington
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07224100CT.gov Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma | — | Recruiting | — | — | — |
NCT06220487CT.gov A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL | — | Recruiting | — | — | — |
NCT05026229CT.gov A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL | — | Unknown | — | — | — |
NCT03595917CT.gov ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML | — | Recruiting | — | — | — |
NCT02883049CT.gov Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations | — | Completed | — | — | — |
NCT00390793CT.gov Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Prednisone (this asset) | University of Washington | P3 | BB · 65 |
| Nilotinib | The University of Hong Kong | P2 | BBB |
| Cytarabine | Novartis Pharmaceuticals | P3 | BBB |
| Blinatumomab | Novartis Pharmaceuticals | P3 | BBB |
| Imatinib | The University of Hong Kong | P3 | BB |
| Dasatinib | SWOG Cancer Research Network | P3 | BB |
| Olverembatinib | Institute of Hematology & Blood Diseases Hospital, China | P3 | BB |
| Methotrexate | Novartis Pharmaceuticals | P3 | BB |
| (+)-Vincristine | Novartis Pharmaceuticals | P2 | BB |
+39 more in the B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2) cohort
Other indications for Prednisone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 74 |
| Diffuse Large B-Cell Lymphoma | — | P4 | BBB · 74 |
| Peripheral T-Cell Lymphoma, Not Otherwise Specified | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Prednisone in B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2). Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/prednisone-b-lymphoblastic-leukemialymphoma-with-t922q341q112
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →